From : National Cancer Institute <nci@updates.cancer.gov>
To : tgabunia@moh.gov.ge
Subject : Blinatumomab Effective for Children with Relapsed Leukemia - Cancer Currents Blog
Received On : 01.04.2021 18:02
Blinatumomab Effective for Children with Relapsed Leukemia - Cancer Currents Blog
National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.

 

 

Blinatumomab Improves Survival in Children with Relapsed Leukemia
04/01/2021
The results of two trials establish blinatumomab (Blincyto) as a new standard treatment for children and young adults with high-risk relapsed B-cell acute lymphoblastic leukemia after remission has been achieved and before a stem cell transplant.
This email was sent to tgabunia@moh.gov.ge using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo